Trial Profile

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amivantamab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary) ; Vitamins
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms PAPILLON
Sponsors Janssen Research & Development; Janssen-Cilag

25 Feb 2026 Planned End Date changed from 30 Sep 2026 to 2 Aug 2027.
25 Feb 2026 Planned primary completion date changed from 30 Sep 2023 to 2 Aug 2027.
01 Nov 2025 The subpopulation analysis of Japanese population(n=34) evaluating amivantamab in combination with chemotherapy, versus chemotherapy alone published in the Cancer Science.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com